Back to top

Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)
December 07, 2017

Read MoreHide Full Article

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Aerie Pharmaceuticals, Inc. (AERI - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in AERI.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen three estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $2.54 a share a month ago to its current level of a loss of $3.42.

Also, for the current quarter, Aerie Pharmaceuticals has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of $1.44 a share from a loss of 67 cents over the past 30 days.  

The stock also has seen some pretty dismal trading lately, as the share price has dropped 9% in the past month.

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical - Drugs industry, you may instead consider a better-ranked stock - Akebia Therapeutics, Inc. (AKBA - Free Report) . The stock currently holds a Zacks Rank #2 (Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Hidden Trades

While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?

Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.

Click here for Zacks' secret trade>>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Akebia Therapeutics, Inc. (AKBA) - free report >>

Aerie Pharmaceuticals, Inc. (AERI) - free report >>


More from Zacks Tale of the Tape

You May Like